The Emerging Roles of the Metabolic Regulator G6PD in Human Cancers
Open Access
- 7 December 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (24) , 17238
Abstract
Metabolic reprogramming, especially reprogrammed glucose metabolism, is a well-known cancer hallmark related to various characteristics of tumor cells, including proliferation, survival, metastasis, and drug resistance. Glucose-6-phosphate dehydrogenase (G6PD) is the first and rate-limiting enzyme of the pentose phosphate pathway (PPP), a branch of glycolysis, that converts glucose-6-phosphate (G6P) into 6-phosphogluconolactone (6PGL). Furthermore, PPP produces ribose-5-phosphate (R5P), which provides sugar-phosphate backbones for nucleotide synthesis as well as nicotinamide adenine dinucleotide phosphate (NADPH), an important cellular reductant. Several studies have shown enhanced G6PD expression and PPP flux in various tumor cells, as well as their correlation with tumor progression through cancer hallmark regulation, especially reprogramming cellular metabolism, sustaining proliferative signaling, resisting cell death, and activating invasion and metastasis. Inhibiting G6PD could suppress tumor cell proliferation, promote cell death, reverse chemoresistance, and inhibit metastasis, suggesting the potential of G6PD as a target for anti-tumor therapeutic strategies. Indeed, while challenges—including side effects—still remain, small-molecule G6PD inhibitors showing potential anti-tumor effect either when used alone or in combination with other anti-tumor drugs have been developed. This review provides an overview of the structural significance of G6PD, its role in and regulation of tumor development and progression, and the strategies explored in relation to G6PD-targeted therapy.Keywords
Funding Information
- National Natural Science Foundation of China (32070715, 82173029, 32270778, 81872273, CSTB2022NSCQ-MSX0612, CSTB2022NSCQ-MSX0611)
- Natural Science Foundation of Chongqing Municipality (32070715, 82173029, 32270778, 81872273, CSTB2022NSCQ-MSX0612, CSTB2022NSCQ-MSX0611)
This publication has 168 references indexed in Scilit:
- Glucose 6-phosphate dehydrogenase deficiency enhances germ cell apoptosis and causes defective embryogenesis in Caenorhabditis elegansCell Death & Disease, 2013
- Glucose‐6‐phosphate dehydrogenase, NADPH, and cell survivalIUBMB Life, 2012
- p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenaseNature Cell Biology, 2011
- ATM activates the pentose phosphate pathway promoting anti‐oxidant defence and DNA repairThe EMBO Journal, 2010
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1Molecular Cell, 2010
- High glucose inhibits glucose‐6‐phosphate dehydrogenase, leading to increased oxidative stress and β‐cell apoptosisThe FASEB Journal, 2009
- Glucose‐6‐phosphate dehydrogenase‐deficient mice have increased renal oxidative stress and increased albuminuriaThe FASEB Journal, 2009
- Cancer Cell Metabolism: Warburg and BeyondCell, 2008
- What is the role of the second “structural” NADP+‐binding site in human glucose 6‐phosphate dehydrogenase?Protein Science, 2008
- The Hallmarks of CancerCell, 2000